Cyberonics: Nearly Half-way to the Summit, Fueled by Positive Data and Boston Scientific's investment
This article was originally published in Start Up
Executive Summary
Cyberonics, ever an unpredictable company, has improved its status with investors. In June, Boston Scientific Corp. purchased 11% of Cyberonics' shares for $50 million. The move buttressed public perception of the value of Cyberonics' technology, a pacemaker-like device that is inserted into a patient's chest and stimulates the vagus nerve to treat epilepsy and, the company hopes, depression. A month later, Cyberonics announced that results of a revised study showed clinically significant improvement in 30% of treated depression patients. The numbers look particularly good because severe depression -a $1 billion opportunity, according to the company--is extremely tough to treat. Just as important for the future, the company has buttressed its management ranks with experienced hires from outside the company, has reorganized its sales team, expanded its national accounts group, and consolidated its sales and service organizations. These changes will not only increase epilepsy sales but also, the company expects, lay a foundation for launch of the depression product.
You may also be interested in...
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
The rise of interest in neurostimulation and neuromodulation approaches is leading venture capitalists and large medical device companies to develop devices to prevent or block seizures. The devices would be used primarily on patients who don't respond to drugs for epilepsy.
Neuromodulation: Devices's Stimulating Growth Market
According to "Opportunities in Global Medical Devices and Diagnostics," a report recently published by Health Research International that forecasts growth rates in seven major clinical segments and 20 major technology segments, neuromodulation will experience the highest growth rate of all the top-tier segments over the next five years, in excess of 18%. The neuromodulation segment posted sales of approximately $1.7 billion in 2005 and will be worth almost $4 billion in 2010, HRI predicts.
Northstar's Buzz
The hottest clinical space in medical devices may very well be stroke and the hottest technology area could be neurostimulation. Northstar combines both opportunities with an innovative system that addresses a largely un-addressed market--chronic stroke--by stimulating the cortex of the brain. And as promising as this therapy is, it may only be the tip of the iceberg for Northstar